Literature DB >> 9518396

Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study.

J B Meigs1, D M Nathan, P W Wilson, L A Cupples, D E Singer.   

Abstract

BACKGROUND: Categorical definitions for glucose intolerance imply that risk thresholds exist, but metabolic risk for type 2 diabetes mellitus or cardiovascular disease may increase continuously as glucose intolerance increases.
OBJECTIVE: To examine the distributions of the following metabolic risk factors across the spectrum of glucose tolerance: overall and central obesity, hypertension, low levels of high-density lipoprotein cholesterol, and increased triglyceride and insulin levels.
DESIGN: Cross-sectional analysis.
SETTING: The community-based Framingham Offspring Study. PARTICIPANTS: 2583 adults without previously diagnosed diabetes. MEASUREMENTS: Clinical data; fasting glucose, insulin, and lipid levels; and glucose and insulin levels taken 2 hours after oral challenge were collected from 1991 to 1993. Glucose tolerance was determined by 1980 World Health Organization criteria. Patients with normal glucose tolerance were categorized into quintiles of fasting glucose. The distributions of each metabolic risk factor and the metabolic sum of the six risk factors were assessed across seven categories from the lowest quintile of normal fasting glucose level through impaired glucose tolerance and previously undiagnosed diabetes.
RESULTS: The mean age of patients was 54 years (range, 26 to 82 years); 52.7% of patients were women. Glucose tolerance testing found that 12.7% of patients had impaired glucose tolerance and 4.8% had previously undiagnosed diabetes. Multivariable-adjusted mean measures of risk factors and odds ratios for obesity, elevated waist-to-hip ratio, hypertension, low levels of high-density lipoprotein cholesterol, elevated triglyceride levels, and hyperinsulinemia showed continuous increases across the spectrum of nondiabetic glucose tolerance. Although a threshold effect near the upper range of nondiabetic glucose tolerance could not be ruled out for triglyceride levels in men and for insulin levels 2 hours after oral challenge in men and women, no other metabolic risk factors showed clear evidence of thresholds for increased risk.
CONCLUSIONS: Metabolic risk factors for type 2 diabetes mellitus and for cardiovascular disease worsen continuously across the spectrum of glucose tolerance categories, beginning in the lowest quintiles of normal fasting glucose level.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9518396     DOI: 10.7326/0003-4819-128-7-199804010-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  36 in total

Review 1.  Modern pharmacotherapies for type 2 diabetes mellitus.

Authors:  S H Hsia
Journal:  J Natl Med Assoc       Date:  2001-09       Impact factor: 1.798

2.  Cardiovascular disease risk of abdominal obesity vs. metabolic abnormalities.

Authors:  Rachel P Wildman; Aileen P McGinn; Juan Lin; Dan Wang; Paul Muntner; Hillel W Cohen; Kristi Reynolds; Vivian Fonseca; MaryFran R Sowers
Journal:  Obesity (Silver Spring)       Date:  2010-08-19       Impact factor: 5.002

3.  Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP × environment regression coefficients.

Authors:  Alisa K Manning; Michael LaValley; Ching-Ti Liu; Kenneth Rice; Ping An; Yongmei Liu; Iva Miljkovic; Laura Rasmussen-Torvik; Tamara B Harris; Michael A Province; Ingrid B Borecki; Jose C Florez; James B Meigs; L Adrienne Cupples; Josée Dupuis
Journal:  Genet Epidemiol       Date:  2011-01       Impact factor: 2.135

4.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

Review 5.  Prediabetes and cardiovascular risk in hypertensive patients.

Authors:  Julian Segura; Cecilia Roldán; Jose A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

6.  Quantifying cardiometabolic risk using modifiable non-self-reported risk factors.

Authors:  Miguel Marino; Yi Li; Michael J Pencina; Ralph B D'Agostino; Lisa F Berkman; Orfeu M Buxton
Journal:  Am J Prev Med       Date:  2014-06-17       Impact factor: 5.043

7.  Fasting but not postprandial (postmeal) glycemia predicts the risk of death in subjects with coronary artery disease.

Authors:  Anil Nigam; Martial G Bourassa; Annik Fortier; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  Can J Cardiol       Date:  2007-09       Impact factor: 5.223

8.  TCF7L2 variants are associated with increased proinsulin/insulin ratios but not obesity traits in the Framingham Heart Study.

Authors:  E S Stolerman; A K Manning; J B McAteer; C S Fox; J Dupuis; J B Meigs; J C Florez
Journal:  Diabetologia       Date:  2009-01-31       Impact factor: 10.122

9.  International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 17.152

10.  Severity of coronary artery disease and retinal microvascular signs in patients with diagnosed versus undiagnosed diabetes: cross-sectional study.

Authors:  Kevin Phan; Paul Mitchell; Gerald Liew; Adam J Plant; Sarah B Wang; Joshua Xu; Joseph Chiha; Aravinda Thiagalingam; George Burlutsky; Bamini Gopinath
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.